1
|
Wang Z, Cui F, Chen Y, Liu H, Zhang Y, Shi Y, Zhang Y, Wang Y, Liang N, Xu L, Liu Y, Liu Z, Shi W. Establishment of an immortalized cell line derived from human adenomyosis ectopic lesions. Tissue Cell 2024; 86:102284. [PMID: 38134573 DOI: 10.1016/j.tice.2023.102284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 11/24/2023] [Accepted: 11/28/2023] [Indexed: 12/24/2023]
Abstract
Because adenomyosis (AM) ectopic primary cells are hard to come by, have a short lifespan, and the characteristics that alter over time, their utility in AM research is constrained. This study aimed to establish a line of immortalized human adenomyosis ectopic cell (ihAMEC) to change this situation. Primary cells were obtained from AM ectopic lesion tissue and then infected with Simian Vacuolating Virus 40 Tag (SV40 T) lentivirus and screened to establish immortalized cells. We verified the main features and found that the ihAMEC could be cultured for more than 50 generations and the proliferation ability of ihAMEC was more active than that of primary cells. The cytoskeleton and cell types of ihAMEC were similar to primary cells and maintained a normal karyotype. The expression of epithelial-mesenchymal transition (EMT) markers, estrogen-metabolizing proteins, and estrogen/progesterone receptors in ihAMEC was similar to the expression seen in primary cells. In addition, the response of ihAMEC under estrogen treatment and Lipopolysaccharide intervention is similar to primary cells. The clonogenic ability of ihAMEC was lower than tumor cells and did not form tumors in tumorigenicity assays. Thus, ihAMEC can be used as in vitro cellular model for pathogenesis and drug development studies regarding AM.
Collapse
Affiliation(s)
- Zilu Wang
- First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Fengxin Cui
- First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Yinuo Chen
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Hongyun Liu
- Department of Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, China
| | - Yiran Zhang
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Yaxin Shi
- First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Yinuo Zhang
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Yanfei Wang
- First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Na Liang
- The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250011, China.
| | - Li Xu
- Department of Gynecology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250001, China
| | - Ying Liu
- Department of Dermatology, PLA 960 Hospital, Jinan, Shandong 250031, China
| | - Zhiyong Liu
- Central Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China; Institute for Literature and Culture of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China.
| | - Wei Shi
- Department of Gynecology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
| |
Collapse
|